BOZEMAN, Mont. — Golden Helix today announced the release of VarSeq 3 and VSWarehouse 3, marking a major milestone in enterprise-scale secondary and tertiary genomic analysis. The release introduces cloud-native deployment options optimized for AWS and Azure, expanded support for hybrid and on-premise support, flexible licensing models including per-sample packaging tailored to small and mid-sized labs. To support these new deployment and licensing models, the release includes seamless integration of secondary analysis and expanded capabilities for long-read sequencing, including accurate detection and interpretation of repeat expansions.

These new capabilities make Golden Helix’s integrated platform ideal for high-throughput labs, national genome initiatives, and smaller diagnostic labs alike, delivering unmatched scalability, automation, and deployment flexibility.

“With VarSeq 3 and its integration into VSWarehouse 3, we are equipping our customers with the infrastructure readiness and data ownership they need to operate at scale—whether in private cloud, hybrid, or fully cloud-native settings,” said Dr. Andreas Scherer, President and CEO of Golden Helix. “This release also expands access to our enterprise-grade platform through per-sample licensing, helping smaller and growing labs take advantage of our full suite of features as they scale.”

Key Highlights of VarSeq 3 and VSWarehouse 3:

• Cloud-Optimized, Hybrid-Ready Deployments
  Customer can deploy on AWS, Azure, or their own private infrastructure with full support for hybrid environments. The architecture supports elastic compute provisioning, seamless updates, and integration with cloud-native storage solutions. Workloads scale dynamically based on demand, whether running on-prem, in the cloud, or across distributed clusters—always under full customer data control.
• Secure Collaboration & Data Federation
  Enable national-level genome data coordination and multi-site collaboration via fine-grained access control and secure data sharing. Native integrations with cloud object storage and third-party NGS repositories streamline cloud-to-cloud data transfer and federated analysis across institutions and geographies.
• Per-Sample Licensing Options
  For the first time, Golden Helix introduces per-sample packages that give smaller labs and those with seasonal or variable sample volumes access to enterprise capabilities, without the upfront cost of unlimited sample licenses.
• Integration for Secondary Analysis
  Unified integration layer for secondary analysis, allowing labs to seamlessly connect upstream pipelines with clinical interpretation workflows. Variant calls, alignment metrics, and quality control outputs from various tools can now be automatically ingested, stored, and analyzed in a single environment.
• Comprehensive Genomic Workflow Automation
  Automate full pipelines across clinical domains including pharmacogenomics, carrier screening, CNV, and repeat expansion analysis. Built-in auto-classification and expert curated annotations reduce interpretation time and support regulatory compliance.
• Long-Read Genomics Support
  This release deepens Golden Helix’s support for long-read sequencing technologies, including repeat expansion detection critical for diagnosing rare disorders like Huntington’s disease and Fragile X. These capabilities extend across both secondary and tertiary workflows.

Golden Helix will present VarSeq 3 and VSWarehouse 3 at the upcoming European Society of Human Genetics (ESHG) conference, taking place May 24–26, 2025 in Milan, Italy. Attendees are invited to visit Booth 510 for live demonstrations and to engage with the Golden Helix team on the future of enterprise-scale genomic analysis.

For more information or to request a demo, visit: www.goldenhelix.com

About Golden Helix

Golden Helix has delivered trusted bioinformatics solutions for over 25 years to hospitals, testing labs, research institutions, and national genome programs around the world. With powerful tools for tertiary analysis and genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and accelerate discoveries in rare diseases and oncology.